119 related articles for article (PubMed ID: 2201430)
1. A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Windschitl HE; O'Connell MJ; Wieand HS; Krook JE; Rubin J; Moertel CG; Kugler JW; Pfeifle DM; Goldberg RM; Laurie JA
Cancer; 1990 Sep; 66(5):853-6. PubMed ID: 2201430
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
[TBL] [Abstract][Full Text] [Related]
3. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
[TBL] [Abstract][Full Text] [Related]
4. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
[TBL] [Abstract][Full Text] [Related]
5. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
[TBL] [Abstract][Full Text] [Related]
7. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
[TBL] [Abstract][Full Text] [Related]
8. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
10. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Presant CA; Ardalan B; Multhauf P; Chan C; Staples R; Green L; Browning S; Carr BI; Chang FF; Thayer W
Med Pediatr Oncol; 1983; 11(3):162-3. PubMed ID: 6222250
[TBL] [Abstract][Full Text] [Related]
11. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
[TBL] [Abstract][Full Text] [Related]
12. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
15. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
[TBL] [Abstract][Full Text] [Related]
16. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation of 5-fluorouracil by PALA.
O'Dwyer PJ
Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
[No Abstract] [Full Text] [Related]
18. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Chiuten DF; Valdivieso M; Bedikian A; Bodey GP; Freireich EJ
Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
[TBL] [Abstract][Full Text] [Related]
20. The role of low-dose PALA in biochemical modulation.
O'Dwyer PJ
Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]